MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$65,428K
Free Cash flow
-$102,650K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturity, redemption or sale of ...
Depreciation
Share-based compensation expense
Others
Negative Cash Flow Breakdown
Net (loss)/profit
Repayment of borrowings
Investment in marketable securit...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2025-06-30
Share-based compensation expense
1,990
Net (loss)/profit
-77,924
Other
56
Decrease in noncurrent assets
-562
Increase in inventories
4,041
Decrease in deferred revenue
-5,812
(decrease)/increase in payables and other current liabilities
-11,407
Unrealized foreign exchange gains
888
Depreciation
4,620
Amortization
355
Increase in borrowings and other non-current liabilities
784
(increase)/decrease in receivables and other operating assets
9,158
Accretion of available-for-sale debt securities
509
Net cash (used in)/provided by operating activities
-101,372
Other
62
Maturity, redemption or sale of marketable securities
76,950
Acquisition of property, plant and equipment
1,278
Investment in marketable securities
16,090
Net cash provided by/(used in) investing activities
59,644
Repayment of borrowings
25,451
Proceeds from exercise of stock options
10
Proceeds from issuance of common stock from offerings, net of commissions and issuance costs
1,775
Net cash (used in)/provided by financing activities
-23,666
Effect of currency exchange rate changes on cash, cash equivalents and restricted cash
-34
Net (decrease)/increase in cash, cash equivalents and restricted cash
-65,428
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturity, redemption or
sale of marketable...
$76,950K
Other
$62K
Net cash provided
by/(used in) investing...
$59,644K
Canceled cashflow
$17,368K
Net
(decrease)/increase in cash, cash...
-$65,428K
Canceled cashflow
$59,644K
Depreciation
$4,620K
Share-based compensation
expense
$1,990K
Increase in borrowings
and other...
$784K
Decrease in noncurrent
assets
-$562K
Amortization
$355K
Other
$56K
Proceeds from issuance of
common stock from...
$1,775K
Proceeds from exercise of
stock options
$10K
Investment in marketable
securities
$16,090K
Acquisition of property,
plant and equipment
$1,278K
Net cash (used
in)/provided by operating...
-$101,372K
Canceled cashflow
$8,367K
Net cash (used
in)/provided by financing...
-$23,666K
Effect of currency
exchange rate changes on...
-$34K
Canceled cashflow
$1,785K
Net (loss)/profit
-$77,924K
(decrease)/increase in payables and
other current...
-$11,407K
(increase)/decrease in receivables
and other operating...
$9,158K
Decrease in deferred
revenue
-$5,812K
Increase in inventories
$4,041K
Unrealized foreign
exchange gains
$888K
Accretion of
available-for-sale debt securities
$509K
Repayment of borrowings
$25,451K
Buy us a coffee
Adaptimmune Therapeutics PLC (ADAP)
Adaptimmune Therapeutics PLC (ADAP)